Please fill out the form below and we will gladly respond as soon as possible.
Synovial sarcoma is a rare and aggressive soft tissue cancer, but new research is helping us better understand how it behaves—and how it may be treated in the future. A recent study using advanced single-cell RNA sequencing has identified four distinct subtypes of synovial sarcoma, each with unique biological features and potential treatment pathways. Why […]
A recent case report highlights a rare GLI1-altered mesenchymal tumor presenting in the pleura (lining of the lung), a location where tumors can closely resemble synovial sarcoma. This case underscores a critical challenge in rare cancers — different tumors can appear similar under imaging and even under the microscope, making accurate diagnosis essential for appropriate […]
Recent industry analyses show that the synovial sarcoma clinical trial pipeline is expanding, with more than 15 companies developing over 20 investigational therapies aimed at improving treatment options for this rare cancer. Although synovial sarcoma remains difficult to treat, the growing number of clinical trials reflects increasing research investment and scientific focus on this disease. […]
Synovial sarcoma is a rare soft tissue sarcoma most commonly treated with surgery, chemotherapy, radiation therapy, and targeted drugs such as pazopanib. However, treatment options can be limited for advanced or metastatic disease. A recently published case report describes a patient with synovial sarcoma who achieved a complete response after receiving targeted therapy based on […]
Synovial sarcoma is a rare and often aggressive cancer that can become difficult to treat once it spreads. Traditional chemotherapy options are limited, and outcomes for metastatic disease remain poor. New research is exploring whether advanced T-cell therapies may offer another option. A recent clinical trial evaluated afamitresgene autoleucel (afami-cel), an engineered T-cell therapy designed […]
A recent market analysis estimates that the global synovial sarcoma treatment market was valued at approximately $832 million in 2023 and is projected to reach $1.6 billion by 2031. While market reports focus on financial projections, they often reflect broader trends in research, drug development, and clinical trial activity. For the synovial sarcoma community, this […]
Content Warning:This article references a published medical case study that includes graphic surgical images involving the head and neck region. While the information may be valuable and informative, some readers may find the images difficult to view. Please proceed with care. Synovial sarcoma most often develops in the extremities, but in rare cases, it can […]
UI Health Care has begun treating eligible patients with synovial sarcoma using a new form of immunotherapy known as T cell receptor (TCR) therapy. This treatment approach represents an important step forward in expanding access to innovative options for people facing advanced synovial sarcoma. A targeted immune-based approach TCR therapy is designed to help the […]
The Synovial Sarcoma Foundation is excited to share that we are on site this week at the 2025 Connective Tissue Oncology Society (CTOS) Annual Meeting in Boca Raton, Florida. This global event brings together leading researchers, oncologists, and experts in sarcoma to discuss the latest data-driven advancements in diagnosis, treatment, and clinical trials. Representing our Board of […]